The purpose of this study is to measure the penetration of TR-700 into subcutaneous adipose tissue and skeletal muscle after a single oral dose of 600 mg TR-701

This study will be conducted in two parts: a Pilot Study and a Main Study. The Pilot Study will be conducted to assess recovery of exogenously administered TR-700 (microbiologically active moiety) via microdialysis. In the Main Study, pharmacokinetics of TR-700 will be determined in both soft tissues (via microdialysis) and plasma after a single oral dose of 600 mg TR-701 (prodrug).

Inclusion Criteria:

• Body mass index of 20 to 29 kg/m2
• Agree not to consume any products containing tobacco, alcohol, quinine, grapefruit, caffeine, or high levels of tyramine
• Agree not to use any other medication
• Female subjects must be postmenopausal (for at least 6 months), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control

Exclusion Criteria:

• History of gastric or duodenal ulcer within 1 year before enrollment
• Has known or suspected hypersensitivity or intolerance to heparin, if an indwelling cannula (e.g., heparin lock) is used
• Recent febrile illness (less than 72 hours before the first intake of study medication).
• Significant blood loss (300 mL) or donation of blood within the 60 days before the Screening visit
• Women who are pregnant or breast-feeding

http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf